Profile | GDS2987 / GI_18375517-I |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 19.7 | 54 |
GSM215244 | HMVEC_vehicle_rep2 | 30 | 58 |
GSM215253 | HMVEC_vehicle_rep3 | 13.5 | 41 |
GSM215254 | HMVEC_atorvastatin_rep1 | 25.9 | 54 |
GSM215282 | HMVEC_atorvastatin_rep3 | 41.4 | 64 |
GSM215344 | HMVEC_atorvastatin_rep2 | 22.4 | 48 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 35.6 | 55 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 23.8 | 43 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 24.7 | 38 |
GSM215294 | HMVEC_SLx2119_rep1 | 8.9 | 32 |
GSM215295 | HMVEC_SLx2119_rep2 | 0.4 | 1 |
GSM215296 | HMVEC_SLx2119_rep3 | 17 | 28 |
GSM215297 | PASMC_vehicle_rep1 | 15.3 | 24 |
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | 12.7 | 21 |
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | 30.6 | 44 |
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | ||
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 71.7 | 71 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 17.4 | 29 |
GSM215327 | PASMC_SLx2119_rep1 | 17.6 | 31 |
GSM215328 | PASMC_SLx2119_rep2 | 44.9 | 60 |
GSM215329 | PASMC_SLx2119_rep3 | 28 | 47 |
GSM215330 | Fibroblasts_vehicle_rep1 | 15.2 | 34 |
GSM215331 | Fibroblasts_vehicle_rep2 | 24.7 | 54 |
GSM215332 | Fibroblasts_vehicle_rep3 | 17.5 | 49 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 10.9 | 29 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 28 | 58 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 34.4 | 60 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 26.2 | 60 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 21 | 54 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 26.3 | 56 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 18 | 46 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 28.7 | 59 |
GSM215341 | Fibroblasts_SLx2119_rep3 |